Ignite Creation Date:
2024-05-06 @ 3:58 AM
Last Modification Date:
2024-10-26 @ 11:42 AM
Study NCT ID:
NCT02425072
Status:
WITHDRAWN
Last Update Posted:
2017-08-10
First Post:
2014-12-11
Brief Title:
NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
Sponsor:
John Villano
Organization:
University of Kentucky
Study Overview
Official Title:
NovoTTFTM-100A System Therapy for Refractory CNS Involved Small Cell Lung Cancer
Status:
WITHDRAWN
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
slow accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The hypothesis of this study is that the addition of NovoTTF-100A System treatment to salvage chemotherapy will significantly increase time to treatment failure in the brain of small cell lung cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None